|Chemical and physical data|
|Molar mass||144.1 kDa g·mol−1|
Common side effects inject pain or redness at the site of injection. Other side effects may include hypersensitivity reactions. It is directed against calcitonin-related polypeptides alpha and beta.
This drug was developed by Eli Lilly. It was approved for medical use in the United States in 2018, becoming the third CGRP inhibitor to do so. When used for migraines it costs about 7,000 USD per year in the United States as of 2019.
- "Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- "FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks". FDA. 4 June 2019. Retrieved 6 June 2019.
- H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
- "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.
- "FDA approves Lilly's migraine drug as first ever cluster headache treatment". CNBC. 4 June 2019. Retrieved 6 June 2019.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|